Host genetic polymorphisms, immune response, and susceptibility to pleural tuberculosis: A systematic review Authors: André Amate Neto, Taylor Endrigo Toscano Olivo, Patrícia Mastroianni, Mariane Nunes de Nadai, Marcela Forgerini, Tales Rubens de Nadai Published: 2026 ABSTRACT AbstractBackgroundPleural tuberculosis is one of the most frequent extrapulmonary manifestations of Mycobacterium tuberculosis infection and is characterized by a pronounced immune-mediated response with a low bacillary burden. Host genetic factors appear to play a central role in its immunopathogenesis.MethodsA systematic review was conducted in accordance with PRISMA guidelines and prospectively registered in PROSPERO (CRD420251051395). Searches were performed across MEDLINE/PubMed, Embase, and SciELO databases, covering publications from 1970 to December 2023. The search strategy combined terms related to pleural involvement, tuberculosis, and genetic polymorphisms.ResultsEight studies fulfilled all eligibility criteria. Polymorphisms in genes involved in innate immunity (SLC11A1/NRAMP1, TLR2, TLR4), cytokine regulation (IFN-γ, IL-10), and host lipid metabolism (CYP7A1) were associated with susceptibility patterns and distinct immunological phenotypes in pleural tuberculosis. These findings underscore the multifactorial nature of pleural disease, driven by complex interactions among genetic determinants and immune pathways.ConclusionsAvailable evidence suggests that pleural tuberculosis reflects genetically mediated amplification of innate and adaptive inflammatory responses, particularly involving macrophage activation pathways and Th1-type cytokine signaling. Integration of genomic, transcriptomic, and immunological data may contribute to improved diagnostic precision, risk stratification, and the development of host-directed biomarkers and personalized therapeutic strategies.Keywords: Pleural tuberculosis, Genetic polymorphisms, Immune response, Susceptibility, Biomarkers Introduction Tuberculosis remains one of the leading causes of infectious morbidity and mortality worldwide, with more than ten million new cases reported annually and a disproportionate burden concentrated in low- and middle-income countries. [1]. Clinically, tuberculosis presents as pulmonary and extrapulmonary forms. Pulmonary tuberculosis is the most prevalent and the main driver of transmission, whereas extrapulmonary manifestations—including pleural, lymphatic, bone, and meningeal tuberculosis—arise through hematogenous or lymphatic dissemination of Mycobacterium tuberculosis and are shaped by specific immunological mechanisms and individual host susceptibility [2]. Among extrapulmonary manifestations, pleural tuberculosis is particularly notable due to its frequency and diagnostic challenges. [3] Unlike pulmonary disease, pleural tuberculosis is primarily driven by an exaggerated host immune response rather than by high bacillary burden. Its pathophysiology involves the entry of mycobacterial antigens into the pleural space, followed by activation of sensitized T lymphocytes and macrophages, leading to a strong Th1-type(T helper 1–type) immune response characterized by the production of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and other pro-inflammatory cytokines.[4]. Granuloma formation is a central mechanism for bacillary containment; however, its effectiveness is modulated by the host’s genetic background, immunological status, and the magnitude of the inflammatory response.[5] This immune-driven process explains the typical clinical presentation of pleural tuberculosis, including lymphocytic exudative effusion and low microbiological yield in pleural fluid analyses. In this context, genetic polymorphisms—natural variations in DNA that influence gene expression and immune function—have been increasingly recognized as key determinants of susceptibility to infectious diseases. In pleural tuberculosis, such variants may influence macrophage activation, cytokine production, and pathogen recognition pathways, thereby modulating both susceptibility and disease phenotype.[5]. Despite advances in understanding genetic susceptibility to pulmonary tuberculosis, comparatively fewer studies have focused specifically on pleural involvement. Whether the same genetic determinants contribute to the distinct immunopathological profile observed in pleural tuberculosis remains unclear. This gap has important implications for improving diagnostic accuracy, understanding disease mechanisms, and identifying potential biomarkers. Therefore, this study aimed to systematically review the available scientific evidence on the role of host genetic polymorphisms in susceptibility, clinical presentation, and immune response in pleural tuberculosis, with particular emphasis on their contribution to disease immunopathogenesis. Material and methods This study is a systematic review conducted in accordance with PRISMA guidelines and prospectively registered in PROSPERO (CRD420251051395). A comprehensive literature search was performed in the MEDLINE/PubMed, Embase, and SciELO databases, covering publications from 1970 to 2023 (date of last search: December 2023). The search strategy combined terms related to pleural involvement, tuberculosis, and genetic polymorphisms using Boolean operators: (pleura OR pleural OR pleurisy) AND (tuberculosis OR Mycobacterium OR tuberculous) AND (genetic OR polymorphism). Although additional databases (e.g., Web of Science, CINAHL, and Google Scholar) and grey literature sources were not included, this limitation is acknowledged as a potential source of publication bias. Eligible studies were original research articles evaluating genetic polymorphisms associated with pleural tuberculosis. Given the nature of the available evidence, only case-control studies were ultimately included in the final analysis. Studies were required to include patients with a confirmed diagnosis of pleural tuberculosis based on at least one of the following: microbiological testing, histopathological findings, or compatible clinical presentation with response to antituberculosis treatment. Studies published in non-English and non–Latin-based languages were excluded, which may represent a potential source of language bias, particularly in regions with high tuberculosis burden. The study selection process included duplicate removal, followed by screening of titles and abstracts. Full-text articles were independently reviewed by two investigators, and disagreements were resolved by consensus. Data extraction included study characteristics (author, year, country, sample size), evaluated genes and polymorphisms, genetic analysis methods, and reported associations. Risk of bias was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case-Control Studies. Due to substantial methodological heterogeneity across studies—including differences in allele frequency distributions, genetic models evaluated, Hardy–Weinberg equilibrium assessment, and variability in effect size reporting (odds ratios and confidence intervals)—a quantitative meta-analysis was not performed. Instead, a narrative synthesis was conducted. Results A combined analysis of the eight included studies demonstrates that susceptibility to pleural tuberculosis is associated with a heterogeneous set of genetic variants influencing both innate and adaptive immunity. Collectively, the findings reinforce that pleural tuberculosis represents a distinct immunological phenotype characterized by a robust inflammatory response (Fig. 1). Prisma flow chart. One of the earliest studies, conducted by [6], identified a significant association between NRAMP1(natural resistance–associated macrophage protein 1) polymorphisms (INT4 and 3′UTR variants) and susceptibility to pleural tuberculosis, suggesting impaired macrophage-mediated intracellular control of Mycobacterium tuberculosis. In contrast, [9] primarily demonstrated associations between SLC11A1/NRAMP1 polymorphisms and pulmonary tuberculosis, with no statistically robust evidence specifically supporting an association with pleural tuberculosis, although extrapulmonary cases were included in the cohort. Studies focusing on cytokine-related genes revealed that the IL-10 ( Interleukin-10)− 1082 A/A genotype (associated with reduced IL-10 production) and the IFN-γ + 874 T allele (associated with increased IFN-γ expression) were more frequent among patients with pleural tuberculosis, supporting a hyperinflammatory Th1-biased response. Additional studies identified associations involving TLR2(Toll-like receptor 2) and TLR4(Toll-like receptor 4) polymorphisms, reinforcing the role of innate immune recognition pathways in susceptibility to pleural tuberculosis. Furthermore, the CYP7A1 (cholesterol 7α-hydroxylase) rs3808607 polymorphism was associated with increased susceptibility to tuberculosis, suggesting a role for host lipid metabolism in modulating host–pathogen interactions. The results of the review are summarized in Table 1. Table 1StudyCountryGene / PolymorphismSampleResultsRisk of Bias (JBI)[6]South KoreaNRAMP1 (INT4, D543N, 3′UTR)56 pleural TB; 45 controlsINT4 | OR = 8.02 (95% CI: 2.42–26.57) | p = 0.01; D543N | OR = 4.16 (95% CI: 0.79–22.01) | p = 0.08; 3′UTR | OR = 5.73 (95% CI: 1.14–28.92) | p = 0.02Moderate[7]ColombiaCD14 (−159C/T)204 pulmonary TB; 33 pleural TB; 18 miliary TB; 12 other extrapulmonary TB; 112 controlsCD14 − 159C/T | OR = Not reported | p > 0.05 (no significant association)Low[8]ColombiaIL10, IFN-γ, TNF-α, TGF-β1, IL6140 pulmonary TB; 30 pleural TB; 20 miliary TB; 135 controlsIL10 − 1082 A/G | p = 0.048 (overall), p = 0.02 (TB group); IFNG + 874 T/A | p = 0.01 (overall), p = 0.004 (TB group); TNF − 308 G/A | p > 0.05; TGF-β1 (codon 10/25) | p > 0.05; IL6 − 174 G/C | p > 0.05; IL10 − 819C/T | p > 0.05; IL10 − 592 A/C | p > 0.05Moderate[9]PeruSLC11A1 (INT4, D543N, 3′UTR)507 pulmonary TB; 78 pleural TB; 36 miliary TB; 9 other extrapulmonary TB; 513 controlsINT4 (pulmonary TB) | OR = 1.72 (95% CI: 1.14–2.62) | p = 0.02; D543N (pulmonary TB) | OR = 1.40 (95% CI: 1.05–1.87) | p = 0.05; 3′UTR (pulmonary TB) | OR = 1.31 (95% CI: 0.98–1.76) | p = 0.10; INT4 (pleural TB) | OR = 1.01 (95% CI: 0.58–1.76) | p = 0.25; D543N (pleural TB) | OR = 1.50 (95% CI: 0.87–2.58) | p = 0.08; 3′UTR (pleural TB) | OR = 1.25 (95% CI: 0.70–2.22) | p = 0.36Low–moderate[10]PeruLTA, TNF, IL1B, IL1RN, IL10, TGFB1, TIRAP, P2X7507 pulmonary TB; 78 pleural TB; 35 miliary TB; 9 other extrapulmonary TB; 513 controlsLTA + 368 (pleural TB, A/A) | OR = 0.09 | p < 0.0001; LTA + 368 (miliary TB, G/A) | OR = 2.90 | p = 0.004; LTA + 368 (extrapulmonary TB, G/A) | OR = 1.67 | p < 0.001; IL10 − 592 (pulmonary TB, C/A) | OR = 0.57 | p = 0.0002; IL10 − 592 (pulmonary TB, A/A) | OR = 0.66 | p = 0.0002; IL10 − 592 (pleural vs pulmonary) | OR = 2.12 | p = 0.018Low[11]ChinaIL10 (−1082 A/G, −819C/T, −592 A/C)123 pleural TB; 112 pulmonary TB; 78 controlsIL10 − 819 T allele | OR = 2.09 (95% CI: 1.11–3.90) | p = 0.021; IL10 − 592 A allele | OR = 2.09 (95% CI: 1.11–3.90) | p = 0.021; IL10 − 819/−592C/C genotype | OR = 0.16 (95% CI: 0.05–0.52) | p = 0.001; IL10 − 1082 A/G | OR = Not significant | p > 0.05Moderate[12]MoroccoCYP7A1 polymorphisms136 pulmonary TB; 50 pleural TB; 138 controlsrs3808607 (AA genotype, PTB vs controls) | OR = 1.94 (95% CI: 1.03–3.65) | p = 0.026; rs3808607 (TB combined vs controls) | OR = 1.91 (95% CI: 1.07–3.42) | p = 0.018; A allele (PTB vs controls) | OR = 1.58 (95% CI: 1.04–2.41) | p = 0.025; A allele (TB combined vs controls) | OR = 1.56 (95% CI: 1.06–2.28) | p = 0.016; rs8192875 / rs8192879 | Not significant (p > 0.05)Moderate[13]ChinaLTA4H polymorphisms734 pulmonary TB; 372 extrapulmonary TB; 150 pleural TB; 78 TB meningitis; 66 lymph node TB; 32 bone TB; 46 other extrapulmonary TB; 888 controlsrs1978331 (extrapulmonary TB) | OR = 1.412 (95% CI: 1.104–1.804) | p < 0.001; rs2540474 (extrapulmonary TB) | OR = 1.380 (95% CI: 1.080–1.764) | p < 0.001; pulmonary TB | Not significant (p > 0.05); pleural TB subgroup | Not significant (p > 0.05)Low Discussion Pleural tuberculosis (TB) represents a distinct immunopathological entity within the spectrum of Mycobacterium tuberculosis infection, characterized by a low bacillary burden and a disproportionately intense host immune response. Unlike pulmonary TB, whose progression is more directly influenced by bacillary replication within lung parenchyma, pleural TB is largely driven by immune-mediated mechanisms, particularly a Th1-type response involving interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which orchestrate granuloma formation and pleural inflammation[4], [14]. The findings of this review support the hypothesis that genetic susceptibility to pleural TB is multifactorial and involves the interplay of innate immunity, cytokine regulation, and metabolic pathways. Importantly, the results suggest that susceptibility to pleural TB may be determined as early as the initial stages of host–pathogen recognition, prior to antigen dissemination into the pleural space. Polymorphisms in genes such as SLC11A1 (NRAMP1) highlight the relevance of macrophage activation and intracellular pathogen handling, whereas variants in IL-10 and IFN-γ underscore the importance of immune balance between pro- and anti-inflammatory responses. A key observation emerging from this review is the differential genetic contribution to pleural versus pulmonary TB. While polymorphisms in SLC11A1 demonstrated significant associations with pulmonary TB, their role in pleural TB appears limited, suggesting distinct immunogenetic mechanisms underlying these phenotypes. Similarly, IL-10 promoter polymorphisms showed consistent associations with pleural TB susceptibility across multiple studies, reinforcing the role of regulatory cytokines in modulating the exaggerated immune response characteristic of pleural disease. These findings contrast with pulmonary TB genetic studies, where associations are more frequently observed with genes involved in pathogen containment and bacterial clearance rather than immune regulation. Another important aspect is the contribution of metabolic and inflammatory mediators, particularly CYP7A1 and LTA4H(leukotriene A4 hydrolase ), which link lipid metabolism and eicosanoide signaling to TB susceptibility. While CYP7A1 variants were associated with increased risk of TB overall, LTA4H polymorphisms demonstrated associations predominantly with extrapulmonary forms, but not specifically with pleural TB. This reinforces the concept that pleural TB occupies a unique position within extrapulmonary disease, with partially overlapping but distinct genetic determinants. Despite these advances, the integration of genetic findings with transcriptomic and epigenetic data remains limited. Emerging transcriptomic studies suggest that pleural TB is associated with distinct gene expression profiles, particularly involving interferon signaling pathways and immune regulatory networks. Furthermore, epigenetic mechanisms such as DNA methylation and histone modifications may influence gene expression independently or in interaction with genetic polymorphisms, thereby modulating host susceptibility. The lack of integration of these multi-omic layers represents a significant gap and an important direction for future research. Another methodological consideration relates to the assessment of Hardy–Weinberg equilibrium (HWE) in control populations. Verification of HWE is a critical quality control step in genetic association studies, as deviations may indicate population stratification, genotyping errors, or selection bias. Although some included studies reported HWE testing, this was not consistently addressed across all studies, which may affect the robustness of the reported associations. This review has several limitations. The included studies are relatively small and heterogeneous in terms of population characteristics, diagnostic criteria, and genetic models analyzed. Additionally, the absence of genome-wide association studies (GWAS) limits the ability to identify novel susceptibility loci. The restriction to English and Latin-based languages may also introduce selection bias, particularly given the high prevalence of TB research in Asian populations. Conclusion This systematic review demonstrates that genetic polymorphisms contribute to susceptibility to pleural tuberculosis through complex interactions involving innate immunity, cytokine regulation, and metabolic pathways. Variants in genes such as IL-10, IFN-γ, SLC11A1, and CYP7A1 appear to play relevant roles in modulating the host immune response, reinforcing the concept that pleural TB is a distinct immunopathological entity within the spectrum of tuberculosis. Unlike previous sections, this conclusion emphasizes the specificity of pleural TB in comparison with pulmonary forms, highlighting that genetic determinants associated with immune regulation may be more relevant than those related to bacillary control. Future advances in this field will require well-powered multicenter studies with standardized diagnostic criteria, clearly defined phenotypic stratification (pulmonary vs pleural TB), and adequately sized cohorts (e.g., >500 cases and matched controls) to ensure sufficient statistical power. In addition, comprehensive genotyping panels targeting key pathways—particularly cytokine regulation (IL-10,IFN-γ, TNF), innate immunity (SLC11A1, TLRs), and inflammatory mediators (LTA4H, CYP7A1)—should be prioritized, alongside the incorporation of genome-wide approaches. Importantly, the integration of genomic, transcriptomic, and epigenetic data will be essential to advance the understanding of pleural TB pathogenesis. Such multi-omics strategies have the potential to identify robust disease-specific molecular signatures, enabling earlier and more accurate diagnosis, improved risk stratification based on host genetic susceptibility, and the development of targeted host-directed therapies tailored to individual immunogenetic profiles. Ethical statement This study was conducted in accordance with internationally accepted ethical standards and principles. As this research is based exclusively on previously published studies and publicly available data, it did not involve direct contact with human participants, animals, or identifiable personal data. Therefore, approval by an institutional review board or ethics committee was not required. All procedures performed in the included studies were conducted in compliance with the ethical standards of the respective institutional and/or national research committees, as reported by the original authors, and in accordance with the Declaration of Helsinki and its later amendments. The authors declare that no ethical concerns are associated with the conduct or reporting of this study. CRediT authorship contribution statement André Amate Neto: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization. Taylor Endrigo Toscano Olivo: Writing – review & editing. Patrícia Mastroianni: Writing – review & editing. Mariane Nunes de Nadai: Writing – review & editing. Marcela Forgerini: Writing – review & editing. Tales Rubens de Nadai: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Contributor Information André Amate Neto, Email: andreamateneto@usp.br. Taylor Endrigo Toscano Olivo, Email: tayloretolivo@usp.br. Patrícia Mastroianni, Email: patricia.mastroianni@unesp.br. Mariane Nunes de Nadai, Email: mariane.nunes@usp.br. Marcela Forgerini, Email: marcela.forgerini@unesp.br. Tales Rubens de Nadai, Email: trnadai@usp.br. References